



Newstar Medical Laboratories - Atlanta
975 Cobb Place Blvd NW, STE 218 Kennesaw, GA 30144
Phone: (678) 505-8016 | Fax:(678) 806-7192
CLIA ID: 11D2145553
Laboratory Director : Robert M David, Ph.D

PATIENT DEMOGRAPHICS	Patient Name: SHARON REYNOLDS	Account: Desert Kidney Associates Baseline	Order Code: NE22-0007325
	DOB: 11/12/1956	Provider: Kanwardeep Sachdeva	Sample Type: Urine
	Patient Gender: F	Accession: 22040700026	Collected: 04/06/2022
	Patient Phone Number: (480) 827-0453	Report Status: AMENDED	Received: 2022-04-07T14:19:02.306386
			Reported: 04/14/2022

PRESCRIPTION LIST	Carvedilol (Coreg , Coreg CR) , Bumetanide (Bumex) , Atorvastatin (Lipitor) , Levothyroxine (Synthroid , Tirosint , Levoxyl) , Glimepiride (Amaryl) , Vitamin D3 (cholecalciferol-D3) (D3-50) , Insulin glargine (Basaglar KwikPen , Lantus , Lantus Solostar Pen , Semglee , Toujeo , Toujeo SoloStar , Lantus OptiClik Cartridge , Toujeo Max SoloStar , Semglee Prefilled Pen , Semglee (Vial)) , Digoxin (Digitek , Digox , Lanoxin , Lanoxicaps , Cardoxin) , Aspirin (Arthritis Pain , Aspi-Cor , Aspir 81 , Aspir-Low , Bayer Plus , Bufferin , Durlaza , Ecotrin , Ecpirin , Miniprin , Vazalore)	DIAGNOSIS CODES
		110 Hypertension

INCONSISTENT			
NOT PRESCRIBED			DETECTED
Class	Test	Cutoff (ng/mL)	Results (ng/mL)
STIMULANT	Caffeine	50	1104.78
[DDI] The risk or severity of adverse effects can be increased when Carvedilol is combined with Caffeine. [DDI] Levothyroxine may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.			

INCONSISTENT		
PRESCRIBED		NOT DETECTED
Class	Test	Cutoff (ng/mL)
STATIN	Atorvastatin	10
[DDI] The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Bumetanide is combined with Atorvastatin. [DDI] The metabolism of Atorvastatin can be decreased when combined with Levothyroxine. [DDI] Glimepiride may decrease the excretion rate of Atorvastatin which could result in a higher serum level.		

CONTRAINDICATION		NOT TESTED
Drug	Contraindication	
Carvedilol	[DDI] The therapeutic efficacy of Glimepiride can be increased when used in combination with Carvedilol. [DDI] The therapeutic efficacy of Insulin glargine can be increased when used in combination with Carvedilol.	
Bumetanide	[DDI] The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Bumetanide. [DDI] The risk or severity of adverse effects can be increased when Bumetanide is combined with Carvedilol. [DDI] The therapeutic efficacy of Glimepiride can be decreased when used in combination with Bumetanide.	
Levothyroxine	[DDI] The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Carvedilol. [DDI] The therapeutic efficacy of Levothyroxine can be increased when used in combination with Acetylsalicylic acid. [DDI] The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Levothyroxine. [DDI] The therapeutic efficacy of Glimepiride can be decreased when used in combination with Levothyroxine.	
Glimepiride	[DDI] The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Glimepiride.	

CONSISTENT			
PRESCRIBED			DETECTED
Class	Test	Cutoff (ng/mL)	Results (ng/mL)
CARDIOVASCULAR	Digoxin	10	132.33
[DDI] The serum concentration of Digoxin can be increased when it is combined with Atorvastatin. [DDI] The serum concentration of Digoxin can be increased when it is combined with Carvedilol. [DDI] The risk or severity of adverse effects can be increased when Bumetanide is combined with Digoxin. [DDI] Levothyroxine may increase the excretion rate of Digoxin which could result in a lower serum level and potentially a reduction in efficacy. [DDI] Glimepiride may decrease the excretion rate of Digoxin which could result in a higher serum level. [DDI] Acetylsalicylic acid may decrease the excretion rate of Digoxin which could result in a higher serum level.			
NSAID	Salicylic Acid	400	Not Detected
Metabolite of Acetylsalicylic Acid [DDI] Acetylsalicylic acid may decrease the excretion rate of Bumetanide which could result in a higher serum level. [DDI] The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Insulin glargine. [DDI] The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Glimepiride. [DDI] Acetylsalicylic acid may decrease the antihypertensive activities of Carvedilol.			

VALIDITY TESTING & SCREENS		
Specimen Validity	Range	Results
PH	4.50 - 8.00	4.4
Specific Gravity	1.01 - 1.03	1.012
Urine Creatinine (mg/dL)	20.00 - 400.00	86.89



Newstar Medical Laboratories - Atlanta
975 Cobb Place Blvd NW, STE 218 Kennesaw, GA 30144
Phone: (678) 505-8016 | Fax:(678) 806-7192
CLIA ID: 11D2145553
Laboratory Director : Robert M David, Ph.D

PATIENT	Patient Name: SHARON REYNOLDS	Account: Desert Kidney Associates Baseline	Order Code: NE22-0007325
DEMOGRAPHICS	DOB: 11/12/1956	Provider: Kanwardeep Sachdeva	Sample Type: Urine
	Patient Gender: F	Accession: 22040700026	Collected: 04/06/2022
	Patient Phone Number: (480) 827-0453	Report Status: AMENDED	Received: 2022-04-07T14:19:02.306386
			Reported: 04/14/2022

NOT PRESCRIBED						NOT DETECTED	
Test	Cutoff (ng/mL)	Test	Cutoff (ng/mL)	Test	Cutoff (ng/mL)	Test	Cutoff (ng/mL)
a-Hydroxytriazolam	30	Buprenorphine	10	Hydromorphone	50	Norpropoxyphene	100
alpha-Hydroxyalprazolam	30	Buspirone	50	Hydroxybupropion	50	Nortriptyline	50
EDDP	100	Butalbital	100	Imipramine	50	Norverapamil	50
Ethyl Glucuronide	500	Carbamazepine	50	Indomethacin	50	O-Desmethyltramadol	100
Ethyl Sulfate	200	Carbamazepine Epoxide	50	Irbesartan	50	O-Desmethylvenlafaxine	100
Fentanyl	2	Carboxycyclopogrel	50	Levetiracetam	50	Olanzapine	25
Fluoxetine	25	Carboxyzolpidem	50	Lorazepam	40	Oxazepam	40
Furosemide	50	Carisoprodol	100	Lurasidone	25	Oxycodone	50
Gabapentin	1000	Celecoxib	50	Meprobamate	200	Oxymorphone	50
Glipizide	10	Chlorpromazine	25	Methadone	100	Paroxetine	25
Glyburide	10	Clonazepam	20	Methotrexate	50	Phenobarbital	100
Lisinopril	50	Clonidine	50	Metoprolol	50	Phentermine	100
Quetiapine	50	Codeine	50	Mitragynine	25	Pioglitazone	50
Carboxybuprofen	400	Cotinine	50	Morphine	50	Pitavastatin	10
Metformin	500	Cyclobenzaprine	50	Mycophenolic acid	50	Pregabalin	150
4-Hydroxydiclofenac	50	Dehydroaripiprazole	20	Naloxone	10	Propranolol	50
7-Aminoclonazepam	40	Desalkylflurazepam	40	Naltrexone	10	Protriptyline	50
7-Aminoflunitrazepam	40	Desipramine	50	Naproxen	100	Pseudoephedrine	50
9-Hydroxyrisperidone	10	Dextrorphan	25	N-Desmethylcitalopram	50	Risperidone	10
Acetaminophen	400	Diazepam	10	N-Desmethylozapine	25	Ritalinic Acid	50
a-Hydroxymidazolam	30	Diclofenac	50	N-Desmethylmirtazapine	25	Rivaroxaban	50
Alprazolam	30	Dihydrocodeine	50	N-Desmethyloanzapine	25	Rosuvastatin	20
Amitriptyline	50	Diltiazem	50	N-Desmethyltapentadol	50	Salicylic Acid	400
Amlodipine	25	Diphenhydramine	50	Norbuprenorphine	30	Sertraline	50
Amphetamine	200	Donepezil	50	Nordiazepam	40	Sitagliptin	50
Apixaban	25	Doxepin	30	Norfentanyl	8	Sufentanil	5
Aripiprazole	20	Duloxetine	50	Norhydrocodone	50	Sumatriptan	50
Atenolol	50	Haloperidol	25	Norketamine	10	Tapentadol	50
Atomoxetine	50	Hydrochlorothiazide	50	Normeperidine	100	Temazepam	40
Baclofen	50	Hydrocodone	50	Noroxycodone	50	Topiramate	50

IMPORTANT DISCLAIMER NOTICE : Newstar warrants that all lab analysis provided is conducted professionally in accordance with all applicable standard laboratory practices and that this data reflects Newstar's attempt to generate accurate results for the specific sample(s) submitted to generate this report. Newstar has developed the tests used during the lab analysis and determined their performance characteristics. The tests have not been cleared or approved by the Food and Drug Administration. The results provided are based on information provided by the Customer. Report results are contingent on the accuracy of the prescription list, diagnosis codes, and government databases used to determine drug contraindications and drug interactions. This data reflects Newstar's attempt to generate accurate results based on the information that was provided to Newstar by the Customer and relying on the established government databases available to Newstar for the specific sample(s). Newstar disclaims any and all liability for any errors and is not responsible for any claims or damages related to the reliability of the test results.